Different biological effects of the two protein kinase C activators bryostatin-1 and TPA on human carcinoma cell lines Klaus G. SteubeDörthe GrunickeHans G. Drexler OriginalPaper Pages: 15 - 23
Phase I study of combined alpha Interferon, alpha difluoromethylornithine (DFMO), and doxorubicin in advanced malignancy Vinod GanjuJohn H. EdmonsonJan C. Buckner OriginalPaper Pages: 25 - 27
Phase II trial of gemcitabine (2,2′-difiuorodeoxycytidine) in patients with adenocarcinoma of the pancreas Ephraim S. CasperMark R. GreenPeter G. Tarassoff OriginalPaper Pages: 29 - 34
Phase II study of low dose cyclophosphamide and intravenous interleukin-2 in metastatic renal cancer Walter D. Y. Quan JrGrace E. DeanRaymond A. Kempf OriginalPaper Pages: 35 - 39
A phase II trial of didemnin B in myeloma Raymond B. WeissBercedis L. PetersonCharles A. Schiffer OriginalPaper Pages: 41 - 43
Phase II study of intravenous melphalan (NSC-8806) in the treatment of patients with advanced squamous carcinoma of the head and neck Merrill S. KiesDavid GrinblattSam Taylor IV OriginalPaper Pages: 45 - 47
FIVB plus GM-CSF in metastatic colorectal cancer Carla I. FalksonGeoffrey FalksonShoshana Keren-Rosenberg OriginalPaper Pages: 49 - 52
Phase II study of carboplatin (CBDCA) in refractory multiple myeloma Bart BarlogieJohn CrowleyKathy Hayden OriginalPaper Pages: 53 - 55
5-Fluorouracil vs. epirubicin vs. 5-fluorouracil plus epirubicin in advanced gastric carcinoma Patrick J. Loehrer Sr.Diane HarryRowan T. Chlebowski OriginalPaper Pages: 57 - 63
Phase II trial of Echinomycin in advanced hormone-resistant prostate cancer Daniel H. ShevrinThomas E. LadHolly Hoyer OriginalPaper Pages: 65 - 66
Phase II trial of menogaril in metastatic adenocarcinoma of the prostate Sarah A. TaylorBrent A. BlumensteinJulian B. Hill OriginalPaper Pages: 67 - 70